SanMelix Laboratories offering is now closed and is no longer accepting investments.


Helping You Heal with Honey

Helping people live happier, healthier lives through superior natural remedies and distinct treatment components to provide faster and more effective wound and skin care.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
SanMelix Laboratories

$134,888.96 Raised


Reasons Icon

First buckwheat honey-based wound dressing patented formulations with anticipated FDA microbial claim for infection control

Reasons Icon

Our advanced wound care dressings will address the antimicrobial resistance (AR) crisis along with hospital acquired infection (HAI) prevention

Reasons Icon

Only dressing that has all three mechanisms of wound healing *Anti-microbial claim *Autolytic debridement * Skin regeneration

Our mission is faster healthier healing


Invest in SanMelix

SanMelix is a bioactive skin and wound care company using the natural healing properties of Buckwheat honey, combined with our advanced bioactive enhancements. SanMelix has created products that aid in the healing of acute, chronic, and minor wounds. Our goal is to enhance our market position in the global Skin and Wound Care market.

BEECure M is not currently available on the market. This product is pending 510(k) submission.

In light of the current Covid-19 Pandemic, there has been a rise in healthcare admissions and an increased awareness of infection control. With IP protection on our BEECure™ M dressing and other pending patents, co-created by a renowned Harvard trained podiatric physician, SanMelix's advanced bioactive skin and wound care products can be used in a host of settings and situations. With the CDC investing $300M+ in 59 state & local health departments to detect and prevent resistant threats, our advanced wound care dressings are ideal for HealthCare Associated Infections (HAIs) and the Antimicrobial Resistance (AR) crisis by reducing microbial growth to prevent life threatening bacteria (e.g. MRSA) from penetrating the dressing while in use.

Our goal is to improve the lives of patients and help speed up the healing process using the natural therapeutic properties that already exist in buckwheat honey. Honey has been used in medicine since 8000 BC because of its unique healing properties and with our team of doctors and scientists, we have enhanced it through the use of broad-spectrum antimicrobials. Dr. Sabacinski has been working in the wound care space for over thirty years, and he knows the patients’ needs for a product that encourages fast wound closure and provides protection from bacteria and infection. Our mission at SanMelix is to help people live happier, healthier lives by providing fast and effective wound and skin care through superior natural remedies. We want to give caregivers, physicians, and the general public the ability to heal wounds using a natural product that has been used for centuries. At SanMelix, the proof is in our buckwheat honey. 


The entire population requires wound care


Human wounds and its burden

  • Many Healthcare Associated Infections HAIs are caused by the most urgent and serious antibiotic-resistant (AR) bacteria and may lead to sepsis or death.
  • Up to one-third of the half billion people with diabetes worldwide will develop a diabetic foot ulcer (DFU). Of these, 17% will require an amputation. 
  • There are few effective therapies for radiotherapy, laser therapy and minor thermal burns

the solution

Using buckwheat honey products, we can solve them

  • Our BEECure™ M (buckwheat honey MGO) patented formulation prevents HAI’s by reducing microbial growth to prevent life threatening bacteria (MRSA) from penetrating the dressing while in use
  • Case studies using BEECure™ M illustrated accelerated healing and skin regeneration on severe limb threatening wounds
  • Our BEECure™ R was developed with buckwheat honey and calming calendula that soothes, hydrates, and revives skin affected by radiation and laser therapy, as well as those exposed to heat and sun. 


    We create products using Buckwheat Honey

    We are focusing on the unique medicinal properties of Buckwheat Honey for tissue regeneration and accelerated healing. Our bioactive buckwheat honey formulations demonstrate intrinsic healing activity with anti-microbial additives to prevent infection. SanMelix has created and will continue to create products utilizing Buckwheat honey. SanMelix currently has two patents on its BEECure™ M formulation and Dr. Sabacinski has co-invented 1 additional patent pending natural Buckwheat Honey BEECure™ medical device which also demonstrated superior clinical outcomes. Studies have proven that buckwheat honey has superior medicinal properties to Manuka honey and other natural remedies. Our products also have higher standardization and broader spectrum anti-microbial activity achieving consistent clinical outcomes. Buckwheat honey also has higher anti-inflammatory and anti-oxidant activities than other products currently being used. 

    Our patented advanced wound care (AWC) dressing will be the only product in the market that meets all the requirements of an ideal wound dressing, debridement, tissue repair, and anti-microbial properties. The anti-oxidant properties in Buckwheat honey assist in wound closure and help to stimulate the wound healing process. This means wounds are healing faster and better without the risk of further complications that could be a great hindrance to the lives of patients. Our Buckwheat honey patented formulation prevents life-threatening bacteria from penetrating through the dressing while it is in use. The nutrients in the honey help spur tissue regeneration because it contains large quantities of easily assailable sugars, amino acids, vitamins, specifically vitamin C. Our (AWC) products are made to heal chronic and difficult to close wounds.

    This product is pending FDA approval.

    Products in Use 

    Our BEECure™ skin and wound care products are categorized into two business segments with each being formulated with the common ingredient of buckwheat honey. Our BEECure™ R -Radiation and Laser skin Care cream launched on Amazon in February 2021 and received the Amazon Choice award in the first month. Our advanced wound care products will also be used in hospitals and rehabilitation centers, by physicians through the use of dressings and ointments.

    BEECure® M is not currently available on the market. This product is pending 510(k) submission.

    Because of the anticipated anti-microbial claim in our AWC dressings, they will be instrumental in the treatment and healing of:

    • Ulcers, diabetic and otherwise
    • Skin grafts
    • Partial Thickness Burns
    • Trauma and triage
    • Surgical Site Infections

    In addition to our AWC products, SanMelix buckwheat honey-based OTC Skin Care cream and ointments can be used for the treatment of:

    • Radiation and Laser Skin Care
    • Sunburns
    • Minor burns
    • Diabetic foot ulcer cream
    • Acne
    • Eczema 


    The difference is in the ingredients 

    Although manuka honey is the most commonly used honey-based wound treatment on the market, studies have shown that buckwheat honey has superior inherent healing properties when compared to manuka honey due to its higher anti-inflammatory and higher anti-oxidant activities. In addition, SanMelix’ s advanced wound care products have been fortified with antimicrobials to ensure a higher standardized and broader spectrum antibacterial activity. Our patented formulation utilized in our AWC dressings permits SanMelix to launch one of the first bioactive honey dressing to make an antimicrobial claim in the U.S. Our honey dressing is currently undergoing the FDA regulatory 510(k) clearance process. Our bioactive dressing will be for any wound type of any depth and severity. The dressing will prevent biofilms from forming, control wound odor, reduce pain and treatment time while being cost-effective and more environmentally sound. 

    Additionally, there will be improved skin and tissue regeneration and debriding action. This prevents the necessity for excess skin grafts or skin substitutes, which run the added risk of infection or rejection. Studies have shown buckwheat honey has bactericidal activity against antibiotic-resistant pathogensIn addition, our 510(k) testing for BEECure M demonstrated the efficacy of our dressing against these super infections.

    The bottom line is that our enhanced Buckwheat honey dressings and ointments are making the lives of patients and doctors easier. We are here to assist in the healing process and make a painful experience as painless as possible. We have seen firsthand the need for such products as the ones we have been creating and know that our BEECure® products are going to be a big step forward in changing the lives of many. 


    Our patented advanced wound care dressing will be the only product in the market that meets all the requirements of an ideal wound dressing, debridement, tissue repair, and anti-microbial properties.

    Characteristics of an ideal wound dressing

    Harnessing the power of nature and science with Buckwheat honey and calendula, SanMelix launched BEECure R radiation and laser skin care. These natural nutrients nourish and hydrate the skin, help restore elasticity and revive dry skin.

    (source, source, source, source, source, source, source)


    Our products have been proven to be safe & effective in early studies 

    • We reached our crowdfunding goal of $1.07M, and have 1,725 investors on StartEngine
    • We launched our BEECure ™ R-radiation and laser skin care on Amazon and
    • We have completed testing on our advanced wound care products and will apply for 510(k) pre-market clearance from the FDA in Q3 2021
    • We secured a secondary US honey supplier and purchased US manufacturer worldwide formulation rights for BEECure™ R -Radiation and Laser Skin Care which reduces our overall manufacturing cost
    • We were granted 2 US patents and 1 Canadian patent and will continue prosecuting our other patent pending formulation application. US trademarks were issued in Q2 2021. Company has also filed an international trademark

    Traction by year:

    On top of this, we are negotiating with other cGMPs to contract manufacture our skin and wound care products. With the funds raised through StartEngine, we plan to complete an evidence-based clinical trial for widespread clinical adoption on our advanced wound care dressing and move to commercialization. Develop, test, and commercialize additional Skin and Wound Care OTC products as well as build up inventory. In addition, we will hire manufacturing, operations, and sales and marketing executives, while continuing to prosecute patents and trademarks. 

    We are thrilled about the future opportunities that are in store for the SanMelix team and the effect our nature-based products will have on healing.


    There are over 50 million reported cases globally of patients suffering from hard-to-close wounds. 15% of these are diabetic foot ulcers that eventually lead to amputation. With natural Buckwheat Honey, proven to have superior healing and skin care outcomes, at its core, BEECure™ is the only dressing to contain the three essential components of skin and wound care. Antioxidants to boost continuous healing, superior anti-bacterial properties for wound cleansing and heightened resistance against infections, and natural anti-inflammatory and humectant properties to soothe, regenerate and revitalize skin.

    SanMelix BEECure™ bioactive skin and wound care products are here to treat everything from a minor scrape to a severe wound and everything in between. Using our unique enhanced Buckwheat honey patented formulations fortified with microbial barriers, we are treating all types of dermal afflictions by speeding up the healing process and reducing pain and the risk of infection. We will be first to market buckwheat honey skin and wound care products in the United States. Our patented advanced wound care dressing will assist with the complexities of combating Hospital Associated Infections (HAIs) across healthcare settings and in the community.

    Honey is a product that has been used all throughout history as a healing and restorative agent, and we are harnessing its natural powers and using our years of scientific and medicinal studies to enhance it. We are regulating it to make it safe for hospital use, as well as selling it OTC to the average consumer. Everyone should be able to experience the benefits of the BEECure™ Buckwheat honey products. 

    Our customers will include the VA & DoD, medical supply distributors, physician networks, hospitals, SNFs as well as indirect sales channel for private label/ white label for OTC opportunities. We will market directly to OTC consumers through the world wide web, pharmacies, retails stores, and indirect sales channel for private label/white label. We are capitalizing on a market that has been desperately in need of a natural and safe product that promotes healing and tissue growth while providing infection control. With our current traction and growth, we will continue to innovate new products and work on opening up key distribution regions across the country. To increase brand awareness, we have hired a successful sales advisor. We now have greater ability to create and design sales materials to engage in digital marketing

    We have a talented and world-renowned physician group who puts patient care first. Our goal is to improve patients' lives in need of healing with our innovative bioactive skin and wound care products.


    Quick Insert
    Drop image
    (or click)

    Loading image

    Advanced Edit
    Drop image
    (or click)

    Loading image


    1150 North 35th Avenue Suite 225
    HOLLYWOOD, FL 33021

    Helping people live happier, healthier lives through superior natural remedies and distinct treatment components to provide faster and more effective wound and skin care.


     Dr. Kenneth Sabacinski
    Dr. Kenneth Sabacinski
    DPM, MHS, FACFAS-Chief Medical Officer (Director)

    Dr. Sabacinski is board certified and has over 30 years’ clinical experience in Foot & Ankle medicine, surgery, and limb salvage. Dr. Sabacinski performed his internship, residency and fellowship training at the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. During his residency at the Beth Israel Deaconess Medical Center and the Joslin Diabetes Center, he was specifically trained in the treatment of acute and chronic diabetic foot ulcers. Dr. Sabacinski is the inventor of multiple advanced wound care patents, including SanMelix's BEECure™ wound care dressings.

    Diana Sabacinski
    Diana Sabacinski
    CPA-Chief Executive Officer /President (Director)

    Mrs. Sabacinski is a Certified Public Accountant (CPA) and Certified Fraud Examiner(CFE) with more than 25 years of C-level management experience in the service, manufacturing, government contracting, and healthcare industries. She is an Entrepreneur and co-founded, co-owned, and operated a multi-location training organization, which was listed on the INC 500 Fastest Growing Companies.

    Ed Quilty

    Ed Quilty


    Ed Quilty is a well accomplished senior business executive who has consistently led, built, and transformed organizations. During his career, he has been the CEO of four publicly-listed companies. Mr. Quilty currently is a Board Member and Advisor to several companies in the healthcare sector with over 25 years of Chief Executive experience in the healthcare industry – primarily in advanced wound care – with expertise in strategic planning, financing, management, and sales and marketing. Mr. Quilty has previously served as the CEO and Chairman of the Board of Derma Sciences Inc.—creator of Medihoney—(now Integra LifeSciences) for over 15 years.

    John Kaufman

    John Kaufman


    Mr. Kaufman has over 40 years of management experience working with and for the Government, business startups, and large-scale manufacturing firms.

    Samuel Hammer

    Samuel Hammer


    Samuel Hammer is the Managing Shareholder for Hammer Navarro and Associates, PA. Sam is a Certified Public Accountant (CPA) and Certified Chartered Global Management Accountant (CGMA) with more than 30 years of healthcare experience serving as a C-Suite Operating Executive, Board of Director and Advisor to Physicians, Employers, Payors, Hospitals, Physician Groups, Law Firms, Manufacturers and Government.

    Hamid Khosrowshahi

    Hamid Khosrowshahi


    FloSure Technologies was founded in 2011 by Hamid Khosrowshahi, a successful entrepreneur who has spent a career in the area of medical devices. He was the guiding hand behind the success of such products as: Exudry, Kollagen (Medifil and Skintemp), DuraGen (dural graft matrix), NeuraGen (nerve guide) and most recently the PRO series of negative pressure wound therapy pumps by Prospera.

    Dr. Jason Green

    Dr. Jason Green

    Director of SanMelix Advisory Board

    Dr. Jason Green, DO, FAOCD, FAAD, Board Certified Dermatologist, is the founder of Green Dermatology & Cosmetic Center in Deerfield Beach, Florida. Providing outstanding dermatological care, state-of-the-art procedures, cutting-edge technology, and personalized patient attention is his priority.

    COL (ret) George E. Peoples, MD, FACS

    COL (ret) George E. Peoples, MD, FACS


    Through his military career as a staff surgeon at a Level I trauma center and multiple combat deployments, Dr. Peoples is the founder of Trauma Insight. He has extensive trauma experience and has developed close relationships with some of the most prominent military and civilian trauma and critical care physicians in the country.

    Marie Williams

    Marie Williams

    Operations Manager

    Marie Williams has 15+ years’ experience in education and healthcare. As the Operations Manager, Marie is directly responsible for ensuring the day-to-day processes at SanMelix run efficiently, while performing customer service activities, accounts receivable, billing and payroll duties.

    Barry Constantine

    Barry Constantine

    Research Scientist-Advisor

    Mr. Constantine has forty 40 years healthcare industry experience with a strong history of advancement within the bio- technology and medical device sectors. Professional skill set includes corporate and division level leadership of product development and project management for early stage and mature organizations. Extensive experience in the areas of pharmaceuticals, tissue engineering, wound healing and skin care. Principal efforts have been the support to start-ups by developing products and FDA regulatory strategies including 510(k) applications.

    Linda Murphy

    Linda Murphy

    Distribution/ Sales-Advisor

    Mrs. Murphy Coordinates successful product launches with large distributors such as Amazon. She received the Gold Stevie Award for Entrepreneur of the Year by the American Business Awards and the Global CEO Excellence award. She was also named a ‘Top 40 Under 40 Rising Star’. 


    SanMelix Laboratories
    Jan 12, 2022
    Class NV Common Stock

    Maximum Number of Shares Offered subject to adjustment for bonus shares



    SanMelix Laboratories, Inc.

    Corporate Address


    1150 North 35th Avenue Suite 225, HOLLYWOOD, FL 33021

    Offering Minimum



    Offering Maximum



    Minimum Investment Amount

    (per investor)




    Offering Type



    Security Name


    Class NV Common Stock

    Minimum Number of Shares Offered



    Maximum Number of Shares Offered



    Price per Share



    Pre-Money Valuation



    *Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

    Investment Incentives and Bonuses*

    If you invest $500+, you will receive 3% bonus shares.

    If you invest $1,000+, you will receive 5% bonus shares.

    If you invest $2,000+, you will receive 10% bonus shares.

    If you invest $5,000+, you will receive 15% bonus shares.

    If you invest $10,000+, you will receive 20% bonus shares.

    All Invested shareholders receive 20% off our Radiation & Laser Skin Care on Amazon. Check Your Email for Discount Code.

    *All perks occur when the offering is completed.

    The 10% Bonus for StartEngine Shareholders

    SanMelix Laboratories Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

    This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.50 / share, you will receive and own 110 shares for $150. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

    This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

    Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

    Irregular Use of Proceeds

    The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.


    Article Image
    Business Wire

    SanMelix Laboratories Wins Stevie® Award in 2021 American Business Awards® for its BEECure™ Line

    Article Image
    The American Business Awards

    Product Management & New Product Awards

    Article Image
    Stock News Now

    SanMelix Laboratories, Inc. - Bioactive Wound Care Company Discusses BEECure™, Approval Process, IP Protection and Growth Drivers

    Article Image
    Health Journal

    SanMelix Lab Courts StartEngine Investors with Honey Wound-Care Products

    Article Image

    Faster and Healthier Healing



    Don't Delay-Get it Today!


    Look No Further This February!


    It's Never Too Late!


    New collaboration

    Hi Everyone,

    We are excited to introduce Mimi Kim, a pioneer in the health and beauty industry spending over thirty years entrenched in research and development, manufacturing, and marketing of ground-breaking beauty products and brands. Presently, she is the President of P&J Medesthetics in Korea - a leading innovator in beauty product formulation who have successfully launched 350+ products from 40+ K-Beauty brands on QVC/HSN USA and TSC Canada since 2017 generating over $70 million. Many of these have sold out on air and surpassed record per minute sales marks. We believe that Mimi is an indispensable addition to the SanMelix Team.


    Bee Well, 



    Maintain A Healthy Skin Barrier

    Dear loyal investor ,
    Good skin integrity is vital to good health. Skin loses integrity as we age and this makes adult skin susceptible to collagen loss, decreased elasticity, increased fine lines, wrinkles and skin conditions. Get your loved ones a BEECure product with a 50% discount that shows how much you care about their well-being!



    BEECure Your Skin!

    Hi Everyone, 

    SanMelix develops formulated solutions that repair, strengthen and maintain a healthy skin barrier to meet key anti-aging, hydration and brightening challenges. Our skin is nature's gift so get your loved ones a BEECure product with a 50% discount that shows how much you care about their well-being!



    No need to break your bank balance

    Hi everyone,
    Formulated with medical-grade buckwheat honey and calming calendula, our skin care is nature's gift. Get your loved ones a BEECure product with a big discount that shows how much you care about their well-being!



    A Gift From Nature

    Hi everyone, 

    This year consider a gift from nature for your loved ones. BEECure® enthusiasts have had great success using BEECure®  on sunburns, burns, sensitive skin, aging skin, sun aftercare (tanning), adult nappy rash, after spa procedures, such as microdermabrasion, microneedling, chemical peels, laser and wax hair removal, tattoos and more! 


    Wellness Gift!

    Hi everyone, 

    If you’re still on the hunt for an awesome gift to go with your Christmas card, you can get your loved ones a BEECure product with a big discount that shows how much you care about their well-being! 


    Bee Santa!


    Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into SanMelix Laboratories.


    StartEngine Owner’s Bonus

    This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.


    Tier 1

    If you invest $500+, you will receive 3% bonus shares.


    Tier 2

    If you invest $1,000+, you will receive 5% bonus shares.


    Tier 3

    If you invest $2,000+, you will receive 10% bonus shares.


    Tier 4

    If you invest $5,000+, you will receive 15% bonus shares.


    Tier 5

    If you invest $10,000+, you will receive 20% bonus shares.




    Cancel anytime before 48 hours before a rolling close or the offering end date.



    We want you to succeed and get the most out of your money by offering rewards and memberships!


    Your info is your info. We take pride in keeping it that way!


    Invest in over 200 start-ups and collectibles!

    With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

    With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

    At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

    Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

    StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

    For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

    For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

    Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

    Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

    Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


    @ 2022 All Rights Reserved

    Apple Store Logo

    Get To Know Us

    Our Team



    Important Message


    Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

    Investment opportunities posted and accessible through the site are of three types:

    1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

    Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

    By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

    Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

    California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

    StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.